疑似非达霉素致全血细胞减少症一例
本文报告一例33岁白人女性因难辨梭菌感染接受非达霉素治疗期间发生全血细胞减少症。首剂后24小时内血小板、血红蛋白和白细胞计数均下降,Naranjo量表评分6分提示很可能相关,停药后3天内三项指标恢复正常。
要点
- 非达霉素首剂后24小时内即可出现血小板、血红蛋白和白细胞下降。
- Naranjo量表评分6分提示非达霉素与全血细胞减少很可能相关。
- 停药后3天内血小板、血红蛋白和白细胞计数恢复正常。
核心结论
- 一例33岁女性在非达霉素治疗CDI期间发生全血细胞减少症,Naranjo量表评分6分提示很可能相关。
- 停药后3天内血小板、血红蛋白和白细胞计数均恢复正常。
研究设计与样本
- 个案报道:一例33岁白人女性,因复发性CDI接受非达霉素治疗。
主要发现
- 入院时血小板172,000/mm3,血红蛋白11.1 g/dL,白细胞3,100 cells/mm3。
- 首剂非达霉素后24小时内(第二剂前)血小板降至156,000/mm3,血红蛋白降至9.9 g/dL,白细胞降至2,600 cells/mm3。
- 治疗最初几天三项指标持续下降;第6天给予非达霉素300 μg皮下注射一次后指标稳定一天,随后总体继续下降。
- 停药后3天内血小板、血红蛋白和白细胞计数恢复正常。
- Naranjo量表评分6分,提示非达霉素与全血细胞减少很可能相关。
临床怎么用
- 使用非达霉素期间应监测血常规,尤其关注血小板、血红蛋白和白细胞计数变化。
- 若出现全血细胞减少,应考虑停药并评估药物相关性。
局限性
- 仅为单个病例报道,因果关系不能完全确定。
- 患者有多种基础疾病和既往多种CDI治疗史,混杂因素可能影响判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A case of pancytopenia in a patient receiving treatment with fidaxomicin for Clostridium difficile infection (CDI) is described. SUMMARY: A 33-year-old Caucasian woman was admitted to the hospital with a chief complaint of loose stools occurring approximately 7 times a day; she also reported fever, nausea, diffuse abdominal pain, and fatigue. The patient had a history of recurrent CDI, recurrent urinary tract infections, nephrolithiasis, chronic hepatitis C, and endometriosis. Her previous therapies for CDI included metronidazole, vancomycin, rifaximin, and fecal microbiota transplantation. On admission, she had a platelet count of 172,000 platelets/mm3, hemoglobin concentration of 11.1 g/dL, and white blood cell (WBC) count of 3,100 cells/mm3. Within 24 hours of the first dose of fidaxomicin and before the second dose, the patient's platelet count fell to 156,000 platelets/mm3, her hemoglobin concentration decreased to 9.9 g/dL, and her WBC count fell to 2,600 cells/mm3. Values for all 3 tests continued to decrease during the first few days of fidaxomicin therapy. One dose of filgrastim 300 μg was administered subcutaneously on day 6 in response to the pancytopenia, after which the platelet, hemoglobin, and WBC values stabilized for a day and then generally declined. Platelet, hemoglobin, and WBC values returned to normal within 3 days of the patient's last dose of fidaxomicin. Use of the Naranjo et al. adverse drug reaction probability scale indicated a probable association (score of 6) between fidaxomicin and the patient's pancytopenia. CONCLUSION: A 33-year-old woman developed pancytopenia during a course of fidaxomicin therapy for CDI. Platelet, hemoglobin, and WBC values returned to normal within 3 days of the final fidaxomicin dose.
引用
- Axtell S, Shokoya A, Yocum C, et al. Probable fidaxomicin-induced pancytopenia. Am J Health Syst Pharm. 2018. PMID: 29626003. doi:10.2146/ajhp170239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。